This clinical trial is focused on studying the effects of a treatment for patients with liver cirrhosis, a condition where the liver becomes severely scarred and unable to function properly. The study involves the use of Human Albumin Grifols 200 g/l, solution for infusion, which is a treatment administered through an intravenous infusion. Human albumin is a protein derived from human blood that helps maintain blood volume and pressure. The trial also involves the use of Sodium Chloride, commonly known as salt, which is used in medical settings to help maintain fluid balance in the body.

The purpose of this study is to validate a predictive biomarker, which is a biological indicator, to see how well patients with cirrhosis and a condition called ascites respond to human albumin therapy. Ascites is a complication of liver cirrhosis where fluid builds up in the abdomen. The study will observe patients over a period of time to see how the treatment affects their health, focusing on liver-related outcomes such as bleeding, infections, and kidney issues. The study will also look at the overall survival of patients over six months, the number of organ failures, and the quality of life of the participants.

Participants in the study will receive the treatment for a maximum of 26 weeks. During this time, researchers will monitor various health indicators to assess the effectiveness and safety of the treatment. The study aims to provide valuable insights into how personalized treatment with human albumin can benefit patients with liver cirrhosis and its complications, potentially improving their quality of life and health outcomes.